InvestorsHub Logo
Followers 829
Posts 119686
Boards Moderated 16
Alias Born 09/05/2002

Re: DFRAI post# 12271

Wednesday, 07/30/2014 2:31:08 PM

Wednesday, July 30, 2014 2:31:08 PM

Post# of 20689
A delay in starting the phase-1 trial of M923 (#msg-104591380) would be somewhat negative, but I can’t see anything calamitous happening with the BAX-MNTA FoB collaboration during 2014.

BAX plans to split into two companies in early 2015, and the pharma spin-off company (which has not yet been named) will inherit the MNTA FoB collaboration.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”